WUP0 Stock Overview
An investment holding company, engages in the manufacture, marketing, and sale of branded prescription and non-prescription drugs, as well as Chinese pharmaceutical products in the People’s Republic of China and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Sanai Health Industry Group Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.048 |
| 52 Week High | HK$0.23 |
| 52 Week Low | HK$0.013 |
| Beta | -1.19 |
| 11 Month Change | -32.39% |
| 3 Month Change | n/a |
| 1 Year Change | -57.33% |
| 33 Year Change | -85.78% |
| 5 Year Change | -65.09% |
| Change since IPO | -98.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| WUP0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | 0.8% |
| 1Y | -57.3% | -18.4% | 9.1% |
Return vs Industry: WUP0 underperformed the German Pharmaceuticals industry which returned -18.4% over the past year.
Return vs Market: WUP0 underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| WUP0 volatility | |
|---|---|
| WUP0 Average Weekly Movement | 59.0% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: WUP0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: WUP0's weekly volatility has decreased from 138% to 59% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 156 | n/a | www.1889hk.com |
Sanai Health Industry Group Company Limited, an investment holding company, engages in the manufacture, marketing, and sale of branded prescription and non-prescription drugs, as well as Chinese pharmaceutical products in the People’s Republic of China and Hong Kong. It operates through three segments: Pharmaceutical Products, Finance Leasing, and Genetic Testing and Molecular Diagnostic Services. The company also engages in development, manufacturing, marketing, and sale of pharmaceutical products; sale of pharmaceutical related software; and provision of consultancy services.
Sanai Health Industry Group Company Limited Fundamentals Summary
| WUP0 fundamental statistics | |
|---|---|
| Market cap | €9.38m |
| Earnings (TTM) | €1.72m |
| Revenue (TTM) | €12.87m |
5.4x
P/E Ratio0.7x
P/S RatioIs WUP0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WUP0 income statement (TTM) | |
|---|---|
| Revenue | CN¥97.54m |
| Cost of Revenue | CN¥79.99m |
| Gross Profit | CN¥17.55m |
| Other Expenses | CN¥4.49m |
| Earnings | CN¥13.06m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.085 |
| Gross Margin | 17.99% |
| Net Profit Margin | 13.39% |
| Debt/Equity Ratio | 11.8% |
How did WUP0 perform over the long term?
See historical performance and comparison